New Subcutaneous Trastuzumab Option for Breast Cancer Tops SPT Week in Review

Top news of the week from Specialty Pharmacy Times.

5. US Can Reduce HIV Infections by 67% by 2030, Study Finds

In order for a substantial decrease of HIV infections in the United States, there needs to be a rapid expansion of prevention and treatment for individuals at risk. Read more.

4. Study: E-Cigarette Use May Lead to Same Cancer-Related Molecular Changes as Cigarettes

A recent study identified genetic changes in e-cigarette users similar to those seen in cigarette smokers. Read more.

3. Is Immunotherapy More Effective than Chemotherapy for Skin Cancer?

Study adds to the ongoing research on immunotherapy and its potential as a viable treatment for patients with cancer. Read more.

2. FDA: Elevated Risk of Blood Clots in Lungs, Death in RA Patients on Higher Dose Tofacitinib

A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial. Read more.

1. FDA OKs Subcutaneous Herceptin Combo Therapy for Certain Breast Cancer Patients

Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer. Read more.